UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~Pursuant~~Date toof ~~Section 13 or 15~~Report (d)Date of ~~the Securities~~Earliest ~~Exchange~~Event ~~Act of 1934~~Reported): September 3, 2010

August 16, 2010 (Date of Report) (Date of Earliest Event Reported)

Trubion Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)


Delaware (State or Other Jurisdiction of Incorporation)		001-33054 (Commission File No.)		52-2385898 (IRS Employer Identification No.)

2401 Fourth Avenue, Suite 1050, Seattle, WA 98121
(Address of Principal Executive Offices, including Zip Code)

(206) 838-0500
(Registrant’s Telephone Number, Including Area Code)

None
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

þ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 28.0201. ~~Results~~Other ~~of Operations and Financial Condition~~Events.

On ~~August~~September 168, 2010, Trubion Pharmaceuticals, Inc.(“Trubion”) announced ~~its~~that ~~financial~~the ~~results~~U.S. ~~for~~Department of ~~the~~Justice ~~second quarter~~and ~~ended~~Federal ~~June 30,~~Trade ~~2010.~~Commission ~~The~~granted ~~full~~early ~~text~~termination of the ~~press~~waiting ~~release~~period ~~issued~~under inthe Hart-Scott-Rodino ~~connection~~Antitrust Improvements Act of 1976 (“HSR Act”), as amended, with respect to the ~~announcement~~planned acquisition of Trubion by Emergent BioSolutions Inc. A copy of the press release is ~~furnished~~filed herewith as Exhibit 99.1 toand ~~this~~is ~~Current~~incorporated ~~Report~~by ~~on Form 8-K~~reference.

Additional Information about the Transaction and Where to Find It

In connection with the transaction, Emergent intends to file with the Securities and Exchange Commission (SEC) a registration statement on Form S-4 and Trubion intends to file with the SEC and mail to its stockholders a proxy statement/prospectus. Investors and stockholders are urged to read the registration statement, the proxy statement/prospectus and other relevant documents filed with the SEC when they become available, as well as any amendments or supplements to the documents because they will contain important information about Emergent, Trubion and the merger.

The registration statement, the proxy statement/prospectus and any other relevant materials (when they become available), and any other documents filed by Emergent and/or Trubion with the SEC, may be obtained free of charge at the SEC’s web site at www.sec.gov. In addition, investors and stockholders may obtain free copies of the documents filed with the SEC by directing a written request to: Emergent BioSolutions Inc., Attn: Investor Relations, 2273 Research Boulevard, Suite 400, Rockville, Maryland 20850, or Trubion Pharmaceuticals, Inc., Attn: Investor Relations, 2401 4th Avenue, Suite 1050, Seattle, Washington 98121. Investors and stockholders are urged to read the registration statement, the proxy statement/prospectus and the other relevant materials when they become available.

Participants in Solicitations

Emergent, Trubion and their respective directors, executive officers and other members of their management and employees may be deemed to be participants in the solicitation of proxies in connection with the merger. Information regarding Emergent’s directors and officers is available in Emergent’s proxy statement on Schedule 14A for its 2010 annual meeting of stockholders, which was filed with the SEC on April 9, 2010. Information regarding Trubion’s directors and executive officers is available in Trubion’s proxy statement on Schedule 14A for its 2010 annual meeting of stockholders, which was filed with the SEC on April 21, 2010. Additional information regarding the interests of such potential participants will be included in the proxy statement and the other relevant documents filed with the SEC when they become available.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release ofissued by Trubion Pharmaceuticals, Inc., dated ~~August 16~~September 8, 2010.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TRUBION PHARMACEUTICALS, INC.
Date: August 16, 2010	By:	/s/ John A. Bencich
Date: September 8, 2010	By:	/s/ John A. Bencich
		John A. Bencich
		Name:	John A. Bencich
		Vice President and Chief Financial Officer
		Title:	Vice President and Chief Financial Officer

INDEX TO EXHIBITS

Exhibit No.		Description
99.1		Press Release ofissued by Trubion Pharmaceuticals, Inc., dated ~~August~~September 168, 2010.

Filing Compare · Trubion Pharmaceuticals, Inc